356591--3/26/2010--NEUROLOGIX_INC/DE

related topics
{product, candidate, development}
{product, liability, claim}
{property, intellectual, protect}
{cost, regulation, environmental}
{personnel, key, retain}
{regulation, government, change}
The Company Has Not Demonstrated that it Can Establish Many Necessary Business Functions. The Company Cannot Ensure that it will be Able to Pursue Further Trials for its Product Candidates or the Timing of any Future Trials. The Company s Future Success Depends Upon Key Physicians and Researchers. The Company is Subject to Stringent Regulation; FDA Approvals. The Company s Research Activities are Subject to Review by the RAC. The Company May Face Substantial Penalties if it Fails to Comply with Regulatory Requirements. The Company Will Need to Conduct Significant Additional Research and Testing Before Conducting Clinical Trials Involving Future Product Candidates. The Company s Future Success Depends Upon Acceptance of its Products by Health Care Administrators and Providers. Events in the General Field of Gene Transfer May Affect the Company s Ability to Develop its Products. Side Effects, Patient Discomfort, Defects or Unfavorable Publicity May Affect the Company s Ability to Commercialize its Products. The Company Does Not Have any Experience in Manufacturing Products for Commercial Sale. The Company s Ability to Manufacture Products Depends upon FDA Approval and Access to Third-Party Manufacturing Facilities. If the Company Fails to Meet Certain Milestones Related to its Intellectual Property Licenses with Third Parties, the Company Could Forfeit License Rights That Are Important to its Business. The Company s Intellectual Property Rights May Be Called into Question or Subject to Litigation. The Company May be Subject to Product Liability Claims in Connection with its Clinical and Pre-Clinical Trials. The Company May Face Liability Due to its Use of Hazardous Materials.

Full 10-K form ▸
related documents
1160308--3/16/2006--ADVENTRX_PHARMACEUTICALS_INC
1029142--3/17/2008--DYNAVAX_TECHNOLOGIES_CORP
765258--3/16/2006--IMCLONE_SYSTEMS_INC
1013238--3/27/2008--ARADIGM_CORP
819050--3/3/2008--VICAL_INC
819050--3/3/2009--VICAL_INC
819050--2/25/2010--VICAL_INC
887151--3/13/2006--ORTHOLOGIC_CORP
819050--2/23/2007--VICAL_INC
949858--3/14/2008--SONUS_PHARMACEUTICALS_INC
907562--3/4/2009--DYAX_CORP
792977--12/1/2006--ADVANCED_MAGNETICS_INC
1047188--3/16/2006--PENWEST_PHARMACEUTICALS_CO
918112--9/13/2007--NEUROBIOLOGICAL_TECHNOLOGIES_INC_/CA/
890465--3/3/2006--NPS_PHARMACEUTICALS_INC
849043--3/14/2006--NEUROGEN_CORP
824068--3/14/2008--ATS_MEDICAL_INC
1029142--3/16/2006--DYNAVAX_TECHNOLOGIES_CORP
1029142--3/16/2007--DYNAVAX_TECHNOLOGIES_CORP
1013238--3/30/2009--ARADIGM_CORP
1396238--3/31/2010--IRIS_BIOTECHNOLOGIES_INC
1396238--3/31/2009--IRIS_BIOTECHNOLOGIES_INC
318154--3/10/2006--AMGEN_INC
936402--3/1/2006--Shire_plc
1012270--3/16/2007--COLLAGENEX_PHARMACEUTICALS_INC
356591--3/25/2009--NEUROLOGIX_INC/DE
1005201--3/16/2006--DEPOMED_INC
887247--3/31/2006--CELLEGY_PHARMACEUTICALS_INC
1140028--3/16/2006--Hana_Biosciences_Inc
72444--3/11/2009--NABI__BIOPHARMACEUTICALS